Results 11 to 20 of about 58,241 (294)
Inhibition of RANKL-Induced Osteoclastogenesis by Novel Mutant RANKL [PDF]
International Journal of Molecular Sciences, 2021 Background: Recently, it was reported that leucine-rich repeat-containing G-protein-coupled receptor 4 (LGR4, also called GPR48) is another receptor for RANKL and was shown to compete with RANK to bind RANKL and suppress canonical RANK signaling during osteoclast differentiation.
Yuria Jang +4 more
openaire +3 more sources
RANKL Expression in Periodontal Disease: Where Does RANKL Come from? [PDF]
BioMed Research International, 2014 Periodontitis is an inflammatory disease characterized by periodontal pocket formation and alveolar bone resorption. Periodontal bone resorption is induced by osteoclasts and receptor activator of nuclear factor-κB ligand (RANKL) which is an essential and central regulator of osteoclast development and osteoclast function.
Bin Chen +5 more
openaire +7 more sources
Osteopetrosis rescue upon RANKL administration to Rankl−/− mice: A new therapy for human RANKL-dependent ARO [PDF]
Journal of Bone and Mineral Research, 2012 Abstract In the last decades the molecular basis of monogenic diseases has been largely unraveled, although their treatment has often remained unsatisfactory. Autosomal recessive osteopetrosis (ARO) belongs to the small group of genetic diseases that are usually treated with hematopoietic stem cell transplantation (HSCT).
LO IACONO N +21 more
core +4 more sources
Targeting RANKL in metastasis [PDF]
BoneKEy Reports, 2014 Acting through its cognate receptor, receptor activator of nuclear factor-κB (RANK), RANK ligand (RANKL) is an essential mediator of osteoclast function and survival. Preclinical data have now firmly established that blockade of tumor-induced osteoclastogenesis by RANKL inhibition will not only protect against bone destruction but will also inhibit the
Dougall, W.C. +2 more
openaire +6 more sources
Relationship between serum RANKL and RANKL in bone
Osteoporosis International, 2011 It is now well accepted that the molecule receptor activator of NFκB ligand (RANKL) and osteoprotegerin play key roles in regulating physiological and pathological bone turnover. There are a large number of published reports of circulating RANKL levels in both health and pathology.
Findlay, D., Atkins, G.
openaire +4 more sources
médecine/sciences, 2008 Given the increasing risk of fractures with aging in western countries, there is a need for the development of safe and efficient anti-osteoporotic drugs for the prevention and treatment of osteoporosis. Recent studies have provided evidence for an essential role of RANKL (Receptor Activator of Nuclear Factor-kappa B Ligand) and its decoy receptor ...
Pierre Marie, Philippe Halbout
openaire +2 more sources
Genetic Polymorphisms of RANK, RANKL and their relation to osteoporosis (Polimorfismos genéticos de RANK y RANKL y su relación con la osteoporosis) [PDF]
, 2012 [eng] Osteoporosis is a systemic skeletal disorder and the most common metabolic bone disease. It is recognized as one of the most prevalent problems facing postmenopausal women in western society. The World Health Organization definition of osteoporosis
Yoskovitz, Guy
core +6 more sources
ارتباط بین غلظت سرمیRANKL با اختلالات قلبی در بیماران بتا تالاسمی ماژور [PDF]
Majallah-i Dānishkadah-i Pizishkī-i Dānishgāh-i ̒ Ulūm-i Pizishkī-i Mashhad., 2020 چکیده مقدمه: بتا تالاسمی ماژور نوعی اختلال اتوزومال مغلوب است که با اریتروپوئز غیر موثر شناخته میشود. تزریق مداوم و ناتوانی بدن در حذف آهن در بدن منجر به اضافه بار آهن شده که باعث ایجاد صدمه به بافت قلب میشود.
الهام محمودی +5 more
doaj +1 more source
Bad to the bone: B cell acute lymphoblastic leukemia cells mediate bone destruction
Molecular & Cellular Oncology, 2021 Skeletal morbidities continue to cause acute and long-term burdens for B-ALL patients underscoring the need to identify the mechanisms underlying these processes and to develop effective therapies.
Sujeetha A. Rajakumar, Jayne S. Danska
doaj +1 more source
Piceatannol attenuates RANKL-induced osteoclast differentiation and bone resorption by suppressing MAPK, NF-κB and AKT signalling pathways and promotes Caspase3-mediated apoptosis of mature osteoclasts [PDF]
Royal Society Open Science, 2019 Osteoclasts are multinuclear giant cells that have unique ability to degrade bone. The search for new medicines that modulate the formation and function of osteoclasts is a potential approach for treating osteoclast-related bone diseases.
Liuliu Yan +4 more
doaj +1 more source